R. Jeffery Karnes

Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer

Daniel E. Spratt, Mohammed Alshalalfa, Nick Fishbane et al. · Clinical Cancer Research · 2019 · 130 citations · Full text

Medicine, Oncology, Urology +17

Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies

Karim Touijer, R. Jeffery Karnes, Niccolò Passoni et al. · European Urology · 2017 · 122 citations · Full text

Medicine, Surgery, Urology +16

Lupeol, a Novel Androgen Receptor Inhibitor: Implications in Prostate Cancer Therapy

Hifzur R. Siddique, Shrawan K. Mishra, R. Jeffery Karnes et al. · Clinical Cancer Research · 2011 · 97 citations · Full text

Medicine, Oncology, Pharmacology +17

EZH2 cooperates with gain‐of‐function p53 mutants to promote cancer growth and metastasis

Yu Zhao, Liya Ding, Dejie Wang et al. · The EMBO Journal · 2019 · 77 citations

Medicine, Cancer Biology, Oncology +14

BMI1 Polycomb Group Protein Acts as a Master Switch for Growth and Death of Tumor Cells: Regulates TCF4-Transcriptional Factor-Induced BCL2 Signaling

Hifzur R. Siddique, Aijaz Parray, Rohinton S. Tarapore et al. · PLoS ONE · 2013 · 36 citations · Full text

Medicine, Molecular Biology, Oncology +17